product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Cyclin D1 (DCS6) Mouse mAb
catalog :
2926P
quantity :
40 ul
price :
123 USD
clonality :
monoclonal
host :
mouse
clone name :
DCS6

The same clone is also sold as:
reactivity :
human, mouse, rat
application :
western blot, immunoprecipitation, immunohistochemistry - paraffin section
citations: 21
Published Application/Species/DilutionReference
  • western blot; human; fig 2
Lee J, Chiang K, Feng T, Chen Y, Chuang S, Tsui K, et al. The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo. Int J Mol Sci. 2016;17: pubmed publisher
  • immunohistochemistry - paraffin section; human; fig 1a
  • western blot; human; fig 4a
Lee E, Jin D, Lee B, Kim Y, Han J, Shim Y, et al. Negative effect of cyclin D1 overexpression on recurrence-free survival in stage II-IIIA lung adenocarcinoma and its expression modulation by vorinostat in vitro. BMC Cancer. 2015;15:982 pubmed publisher
  • western blot; human
Wang Y, Han A, Chen E, Singh R, Chichester C, Moore R, et al. The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells. Int J Oncol. 2015;46:1924-34 pubmed publisher
  • western blot; human; fig 6
Zhang X, Ma W, Cui J, Yao H, Zhou H, Ge Y, et al. Regulation of p21 by TWIST2 contributes to its tumor-suppressor function in human acute myeloid leukemia. Oncogene. 2015;34:3000-10 pubmed publisher
  • western blot; rat; 1:1000; fig  6
Li R, Xu D, Ma T. Lovastatin suppresses the aberrant tau phosphorylation from FTDP-17 mutation and okadaic acid-induction in rat primary neurons. Neuroscience. 2015;294:14-20 pubmed publisher
  • western blot; human; fig 4c
Moniz S, Bandarra D, Biddlestone J, Campbell K, Komander D, Bremm A, et al. Cezanne regulates E2F1-dependent HIF2α expression. J Cell Sci. 2015;128:3082-93 pubmed publisher
  • western blot; human
Lee J, Chung L, Chen Y, Feng T, Chen W, Juang H. Upregulation of B-cell translocation gene 2 by epigallocatechin-3-gallate via p38 and ERK signaling blocks cell proliferation in human oral squamous cell carcinoma cells. Cancer Lett. 2015;360:310-8 pubmed publisher
  • western blot; human
Weidmann H, Touat-Hamici Z, Durand H, Mueller C, Chardonnet S, Pionneau C, et al. SASH1, a new potential link between smoking and atherosclerosis. Atherosclerosis. 2015;242:571-9 pubmed publisher
  • western blot; human; 1:1000
Zanotto-Filho A, Braganhol E, Klafke K, Figueiró F, Terra S, Paludo F, et al. Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. Cancer Lett. 2015;358:220-31 pubmed publisher
Ekyalongo R, Mukohara T, Funakoshi Y, Tomioka H, Kataoka Y, Shimono Y, et al. TYRO3 as a potential therapeutic target in breast cancer. Anticancer Res. 2014;34:3337-45 pubmed
Pickhard A, Gröber S, Haug A, Piontek G, Wirth M, Straßen U, et al. Survivin and pAkt as potential prognostic markers in squamous cell carcinoma of the head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117:733-42 pubmed publisher
Thomas S, Malzer E, Ordonez A, Dalton L, van 't Wout E, Liniker E, et al. p53 and translation attenuation regulate distinct cell cycle checkpoints during endoplasmic reticulum (ER) stress. J Biol Chem. 2013;288:7606-17 pubmed publisher
Liu F, Korc M. Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012;11:2138-48 pubmed publisher
Ekyalongo R, Mukohara T, Kataoka Y, Funakoshi Y, Tomioka H, Kiyota N, et al. Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line. Invest New Drugs. 2013;31:293-303 pubmed publisher
Jonckheere N, Skrypek N, Merlin J, Dessein A, Dumont P, Leteurtre E, et al. The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. PLoS ONE. 2012;7:e32232 pubmed publisher
Cai Y, Cui W, Chen W, Wei P, Chi Y, Zhang P, et al. The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms. Cancer Cell Int. 2013;13:57 pubmed publisher
Chang S, Chang C, Lee D, Lee P, Yeh Y, Yeh C, et al. Tumor cell cycle arrest induced by shear stress: Roles of integrins and Smad. Proc Natl Acad Sci U S A. 2008;105:3927-32 pubmed publisher
Ramasamy R, Tong C, Yip W, Vellasamy S, Tan B, Seow H. Basic fibroblast growth factor modulates cell cycle of human umbilical cord-derived mesenchymal stem cells. Cell Prolif. 2012;45:132-9 pubmed publisher
Moser R, Toyoshima M, Robinson K, Gurley K, Howie H, Davison J, et al. MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiency. Mol Cancer Res. 2012;10:535-45 pubmed publisher
Dai Y, Liu L, Zeng T, Zhu Y, Li J, Chen L, et al. Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. Biochem Biophys Res Commun. 2013;436:711-8 pubmed publisher
Tian J, Berton T, Shirley S, Lambertz I, Gimenez-Conti I, DiGiovanni J, et al. Developmental stage determines estrogen receptor alpha expression and non-genomic mechanisms that control IGF-1 signaling and mammary proliferation in mice. J Clin Invest. 2012;122:192-204 pubmed publisher
product information
SKU :
2926P
Product-Name :
Cyclin D1 (DCS6) Mouse mAb
Size :
40 ul
Price-(USD) :
123 USD
Species-x-Reactivity :
H, M, R
Applications :
Immunoprecipitation
Product-Category :
Cell Cycle / Checkpoint Control
Shipping-Temp :
COLD
Storage-Temp :
-20°C
Product-Type :
Monoclonal Antibody
MW :
36
Host :
Mouse
Target :
Cyclin D1
Primary-Protein :
CCND1
Alt-Names :
B-cell CLL/lymphoma 1,B-cell lymphoma 1 protein,BCL-1,BCL-1 oncogene,BCL1,CCND1,CycD1,D11S287E,G1/S-specific cyclin D1,G1/S-specific cyclin-D1,PRAD1,PRAD1 oncogene,U21B31,cyclin D1
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.